Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Contact information



Primary contact

Prof David Dearnaley


Contact details

Royal Marsden NHS Trust
United Kingdom

Additional identifiers

EudraCT number number


Protocol/serial number


Study information

Scientific title

A randomised phase III multi-centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer



Study hypothesis

To test the hypothesis that hypofractionated radiotherapy schedules for localised prostate cancer will improve the therapeutic ratio by either:
1. Improving tumour control.
2. Reducing normal tissue side effects.

Ethics approval

London MREC, 17/08/2004, ref: 04/MRE02/10

Study design

Randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Localised prostate cancer


1. Control group: neoadjuvant hormone therapy and external beam radiotherapy (IMRT) 74 Gy in 37 fractions over 7.5 weeks.
2. Hypofractionation group one: neoadjuvant hormone therapy and external beam radiotherapy (IMRT) 57 Gy in 19 fractions over four weeks.
3. Hypofractionation group two: neoadjuvant hormone therapy and external beam radiotherapy (IMRT) 60 Gy in 20 fractions over four weeks.

Intervention type



Drug names

Primary outcome measures

Acute and late radiation induced side-effects

Secondary outcome measures

1. Freedom from prostate cancer recurrence
2. Development of metastases
3. Recommencement of hormonal treatment for disease occurrence
4. Cause specific and overall survival
5. Aspects of quality of life and health economics
6. Models of normal tissue and tumour control

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Histologically confirmed, previously untreated locally confined adenocarcinoma of the prostate
2. Clinical stage T1b – T3a, N0, M0 (1997 TNM system)
3. Prostate Specific Antigen (PSA) less than 40 ng/ml
4. Estimated risk of lymph node metastases less than 30%
5. World Health Organisation (WHO) performance status zero or one
6. Normal blood count (Hb more than 11 g/dl, white blood cell count [WBC] more than 4000/mm^3, platelets more than 100,000/mm^3)
7. Written informed consent

Participant type


Age group




Target number of participants

3170 (Added 12/09/2011: 3216 actually recruited)

Participant exclusion criteria

1. Prior pelvic radiotherapy or radical prostatectomy
2. Previous androgen deprivation
3. Life expectancy less than ten years (less than five years for poorly differentiated cancers)
4. Previous active malignancy within the last five years other than basal cell carcinoma
5. Co-morbid conditions likely to impact on the advisability of radical radiotherapy (e.g. previously inflammatory bowel disease, previous colorectal surgery, significant bladder instability or urinary incontinence)
6. Full anticoagulation with e.g. Warfarin or Heparin
7. Hip prosthesis or fixation which would interfere with standard radiation beam configuration

Recruitment start date


Recruitment end date



Countries of recruitment

Ireland, New Zealand, Switzerland, United Kingdom

Trial participating centre

Royal Marsden NHS Trust
United Kingdom

Sponsor information


Institute of Cancer Research (UK)

Sponsor details

123 Old Brompton Road
United Kingdom

Sponsor type

Research organisation



Funder type

Research organisation

Funder name


Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2012 preliminary safety results in:
2012 prospective analysis study in:
2015 results in:
2016 results in:

Publication citations

  1. Preliminary safety results

    Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial., Lancet Oncol., 2012, 13, 1, 43-54, doi: 10.1016/S1470-2045(11)70293-5.

  2. Prospective analysis study

    Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM, Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study., Lancet Oncol., 2012, 13, 1, 65-77, doi: 10.1016/S1470-2045(11)70302-3.

  3. Results

    Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E, Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial., Lancet Oncol, 2015 , doi: 10.1016/S1470-2045(15)00280-6.

  4. Results

    Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 2016 , doi: 10.1016/S1470-2045(16)30102-4.

Additional files

Editorial Notes

27/06/2016: publication reference added. 04/01/2011: the target number of participants was changed from 450 to 3170. 12/09/2011: the source of funding was changed from NCRI Southern Prostate Cancer Collaborative to CTAAC.